Parabilis Medicines (PBLS) stock

Protein-targeting medicines , market cap $3.4B

Protein-targeting medicines

Worth $3.4B

Pre-market

$28.91

+1.33%

Close $28.53 +2.33%

As of 9:10 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Below Average

In its industry

#103of 281

Biotech

Checks firing

4of 14

Transition

From its high

-32.8%

under its best since listing

PBLS's Quality Score rose 2 points on Fri, Nov 6, to 2. It closed near its high of the day (2 chart checks started).

New listing, trading since Jun 10, 2026. 105 trading days so far, so 3 of the 14 chart checks wait for more history.

Follow PBLS's trial news. Pro members can get an alert when Parabilis Medicines files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PBLS files news on its trialSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…mature clinical data from the ongoing Phase 1/2 study in desmoid tumors during the fourth quarter of 2026”Trial data · SEC filing · Aug 13

Key facts on PBLS

Key facts on PBLS
Holding it back	Moves 8.4% a day with no profit behind it
Latest filing	8-K, Nov 5 Signed a material agreement

PBLS in the news

ReportExpected to report Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It closed -4.7% after its last report. Past reports ›

PBLS catalysts

Coming up

After its last report it closed -4.7%.

5 more coming up, with sizes and sources, for Pro members.

What's next for PBLS, and how long its cash lasts

Next step the company has named

Q4 2026“Expect to present more mature clinical data from the ongoing Phase 1/2 study in desmoid tumors during the fourth quarter of 2026”Trial data · SEC filing · Aug 13

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: FOG-001 in Locally Advanced or Metastatic Solid TumorsPhase 1/2 · Recruiting · 619 people · main data estimated Apr 1, 2027 · NCT05919264

For Pro members: 4 more milestones and 6 filings.

Cash runway Jun 30 balance sheet

$1.1B in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2030” (8-K, Aug 13).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director RA CAPITAL MANAGEMENT, L.P. bought 244,593 shares on Jul 22. 3 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Mathai Mammen buys or sells

For Pro members: every trade, and Mathai Mammen’s 3 filings and quotes.

Get an alert when PBLS files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why PBLS scores 2

Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

+4Chart checks 4 of 14 firing right now, one point each
−2Volatility moves 8.4% a day with no profit or positive free cash flow over four quarters on fileA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Long-term trend, Run-up, Size, Profit, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on PBLS and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:10 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when PBLS's Quality Score turns up

A free account. No card.

How PBLS ranks in Biotech

PBLS is #103 of 281 by Quality Score.

How PBLS ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	OVIDOvid Therapeutics		Open for its score
	PALIPalisade Bio		Open for its score
	PBYIPuma Biotechnology		Open for its score
	PCRXPacira BioSciences		Open for its score
103	PBLSParabilis Medicines	4/14	2

Cash and short-term investments: PBLS $1.12B, ARWR $1.60B.

When does PBLS report earnings, and what happens after?

Expected to report Thu Nov 12, before the open (in 3 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What PBLS reported on Aug 13, 2026

The quarter

The figures are not read from the release yet.

“The increase in net loss of $17.7 million was primarily driven by increased operating expenses.”

The filing on EDGAR

Where the sales came from

PBLS's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase of $9.3 million was primarily driven by ongoing investment in the clinical development of zolucatetide across a number of indications, increased employee-related costs (including stock-based compensation) associated with increased hiring to support the advancing clinical pipeline, and progression of the Company’s preclinical β-catenin, ERG, and AR ON degrader programs.”

From its results filing (SEC filing · Aug 13)

1 more sentence, for Pro members.

The numbers

Market value: $3.4B; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on PBLS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 1

-4.7%

Aug 13

Reported	When	Gap	Reaction	5 days
Aug 13, 2026Before open	Before open	+0.7%	-4.7%	+10.4%

PBLS closed higher after 0 of its last 1 report.

Everyone reporting earnings this week

PBLS has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on PBLS, and all 14 on every stock.Get in free →

PBLS RSI on Nov 6: 49.3, below its 50-day average

Not scored

RSI 49.3, MACD above signal. Not scored.13 readings

The deep dive on PBLS

What it does and how it makes money1 findingFor Pro members1 finding on what PBLS does and how it makes money, for Pro members
Where it stands1 finding$1.12B in cash and short-term investments against $6.41M of debt on Jun 30, 2026.Balance sheet of Jun 30, 2026, filed Aug 13, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades PBLS, for Pro members
Against its closest peers1 peerCash and short-term investments: PBLS $1.12B, ARWR $1.60B.

4 more findings on PBLS, each with its source, for Pro members.

PBLS share count over time

Shares: 14.3 times the count a year ago (to Jun 30).

Offerings, shelves, and splits of PBLS, from its filings
From its filings	Filed
Raised $670M in a sale of shares, about 19% of its market value	Jun 10, 2026
Registered shares for sale (S-1)	May 19, 2026

PBLS insider trades

3 insiders bought $441M across 14 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyRa Capital Management, L.P.$2.7M10% ownerat $27.13 on Jul 20, filed Jul 22

BuyRa Capital Management, L.P.10% owner$2.7Mat $27.13 on Jul 20, filed Jul 22

All 14 insider filings on PBLS from the last six months, for Pro members.

All PBLS insider trades

PBLS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Alan SebulskyDirector · 4 trades
Alexis BorisyDirector · no trades on file
Edward M. FitzgeraldDirector · no trades on file

See insider trades by person

Which ETFs hold PBLS?

In ETFs: PBLS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Parabilis Medicines

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Cambridge, MAparabilismed.com

Listed on Nasdaq on Jun 10, 2026, and is 43% above its $20 offer price now. Its IPO filing and first days

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on PBLS and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn PBLS's score around: 3 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJul 22Ra Capital Management, L.P. bought PBLS$2.7M at $27.13, filed Jul 22

Alerts are optional.

See PBLS's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: PBLS's Quality Score is 2 (Below Average), #103 of 281 in Biotech. Insiders bought $441M in the last 6 months (Form 4).

What does PBLS's Quality Score say?

PBLS scores 2 today, which Breakaway calls Below Average. It is #103 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Shares: 14.3 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is PBLS's Quality Score?

PBLS scores 2 today, which Breakaway calls Below Average (0 to 5). That is #103 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PBLS's 2.

Are insiders buying PBLS?

3 insiders bought $441M across 14 filings in the last 6 months. No open-⁠market sales on record. The newest is Ra Capital Management, L.P., 10% owner, who bought $2.7M on Jul 20. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.